Drug General Information
Drug ID
D0C0EO
Former ID
DNC003749
Drug Name
CP-105696
Drug Type
Small molecular drug
Indication Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51] Discontinued in Phase 1 [540322], [545980]
Structure
Download
2D MOL

3D MOL

Formula
C28H28O4
InChI
InChI=1S/C28H28O4/c29-26-22(16-19-8-10-21(11-9-19)20-6-2-1-3-7-20)18-32-25-17-23(12-13-24(25)26)28(27(30)31)14-4-5-15-28/h1-3,6-13,17,22,26,29H,4-5,14-16,18H2,(H,30,31)/t22-,26+/m0/s1
InChIKey
KMNLXCBYBKHKSK-BKMJKUGQSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Leukotriene B4 receptor 1 Target Info Inhibitor [551327]
Leukotriene B4 receptor 2 Target Info Inhibitor [551327]
KEGG Pathway Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Leukotriene receptors
G alpha (q) signalling eventsR-HSA-391906:Leukotriene receptors
G alpha (q) signalling events
WikiPathways Nucleotide GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK
GPCR downstream signaling
GPCRs, Other
References
Ref 540322(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3368).
Ref 545980Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005644)
Ref 5513273-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.